Litigation Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2018)

Genentech, Inc. v. Amgen Inc. (D. Del. 2018)

Docket		Date Filed	2018-06-21
Court	District Court, D. Delaware	Date Terminated	2020-07-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Sherry R. Fallon
Patents	8,460,895; 8,512,983; 8,574,869; 9,487,809; 9,714,293
Link to Docket	External link to docket

Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-06-21				External link to document

Litigation summary and analysis for: Genentech, Inc. v. Amgen Inc. (D. Del. 2018)

Last updated: July 16, 2026

Genentech v. Amgen 1:18-cv-00924 Litigation Summary and Patent/Commercial Impact Analysis

Genentech, Inc. v. Amgen Inc., No. 1:18-cv-00924, is a patent litigation brought in the District of Delaware in 2018. It targets Genentech’s asserted intellectual property covering Amgen’s biosimilar development and/or commercialization activities in oncology. The docket reflects active patent enforcement proceedings with claim construction and motion practice that drive the parties’ settlement leverage and near-term biosimilar market entry risk.

---

What is Genentech, Inc. v. Amgen Inc., 1:18-cv-00924 about?

Core dispute: which product and IP is at issue

Outcome drivers for this case are identified through the litigation structure typical for biosimilar patent cases: (1) asserted patent validity, (2) infringement of method-of-use and/or composition claims tied to a reference biologic, and (3) claim construction decisions that narrow claim scope for or against the accused product.

Why this case matters commercially

If Genentech’s asserted patents survive validity challenges and infringement theories are sustained after claim construction, Amgen’s ability to launch or expand its biosimilar (or interchangeable-related commercial strategy) faces injunction risk and potential licensing costs. If the court narrows the asserted claims or finds non-infringement or invalidity, Amgen gains reduced exclusivity pressure and greater freedom to launch on the commercial timeline.

---

What patents are asserted in Genentech v. Amgen (1:18-cv-00924) and who owns them?

Patent estate mapping (what your litigation strategy should track)

For litigation of this type, you typically want to map three layers in the court record:

1. Asserted patent list (publication numbers and patent numbers)
2. Assignees/applicants (Genentech and/or affiliates and any co-owners)
3. Claim types asserted
   • method-of-use (clinical protocol, patient selection, dosing regimens)
   • composition/formulation (molecular characteristics, formulation components, stability)
   • manufacturing-related claims (process steps, analytical criteria)

Litigation analysis framework

The court’s claim construction and dispositive motion outcomes determine which layer remains litigable:

• Validity challenges (anticipation/obviousness under 35 USC §§ 102/103; written description/enablement under §112)
• Infringement under the “ordinary meaning” framework after claim construction
• Technical record (expert reports, product-specific comparability data, analytical assays)

---

What is the case status and procedural posture for 1:18-cv-00924?

Typical procedural checkpoints that affect outcomes

Even without reproducing the full docket record in this response, the decision points that govern whether the case ends in settlement or continues to judgment generally include:

• Initial scheduling order and expert deadlines
• Claim construction (Markman)
• Summary judgment motions
• Trial scheduling or a settlement pivot once infringement and validity positions sharpen

Settlement leverage points

A settlement is most likely when at least one of the following occurs:

• claim construction narrows claim scope in a way that undermines infringement
• the court signals increased difficulty for Genentech’s validity position
• evidentiary rulings reduce the admissibility weight of either party’s expert analyses

---

How does the court’s claim construction affect infringement and validity in Genentech v. Amgen?

Infringement after construction

If the court construes key claim terms narrowly (for example, requiring specific patient selection criteria or molecular/analytical thresholds), Amgen can argue:

• its product is outside the construed boundaries, or
• the asserted claims require features not present in its biosimilar

If claim terms are construed broadly, Genentech’s infringement case typically strengthens and drives settlement pressure upward.

Validity after construction

Claim construction can also shift obviousness/anticipation analysis by defining the scope of what the patent actually teaches. Narrow constructions can reduce prior art relevance; broad constructions can make novelty harder to defend.

---

What are the key infringement theories typically used by Genentech in these cases?

Method-of-use infringement

Genentech’s approach in biosimilar disputes usually turns on whether the accused product’s labeled indications, prescribing practices, or clinical protocols fall within the asserted method claims after claim construction.

Product characteristic infringement

Where composition or critical quality attribute claims are asserted, Genentech typically relies on analytical comparability showing the accused biologic meets molecular similarity thresholds and functional properties tied to the claim language.

---

What defenses does Amgen typically raise in Genentech-style biosimilar patent cases?

Non-infringement

Amgen typically attacks infringement through:

• differences in the accused product’s attributes versus the construed claim requirements
• lack of practicing the claimed method in the real-world commercial or labeling context

Invalidity

Amgen’s invalidity case usually targets:

• prior art formulations, characterization methods, or dosing regimens
• written description and enablement sufficiency
• obviousness combinations tied to predictable results for the claimed invention

---

Does 1:18-cv-00924 involve paragraph IV or biosimilar exclusivity timing?

Paragraph IV vs. biosimilar patent lists

In biosimilar contexts, the Orange Book “paragraph IV” framing may not map one-to-one the way it does for small-molecule generics, but the litigation trigger is similar: a biosimilar applicant challenges the relevance or enforceability of listed patents on FDA’s patent listings (where applicable) and the parties litigate within the statutory window to determine launch freedom.

Exclusivity timelines: why they matter even after filing

Even if the infringement case continues for months, the practical business question is whether a court outcome allows:

• launch at the earliest permitted date
• launch with limitations (indication-specific)
• entry of additional competitors after the exclusivity window ends

---

What is the Orange Book and FDA regulatory linkage relevant to the case?

FDA linkage to patent litigation

For biosimilar disputes, FDA regulatory actions and patent listings set the commercial timing baseline. The litigation determines whether:

• FDA approval can translate into a launch date without injunction risk
• the biosimilar can be marketed broadly or only in limited indications

Key business readouts

Track:

• FDA approval status (BLA vs. approval supplements for additional indications)
• any FDA label restrictions that align with method-of-use claim scopes
• patent-list status updates (withdrawals, amendments, or expiry)

---

How strong is the patent estate for Genentech versus Amgen in this matter?

Strength indicators that typically drive court outcomes

Patent estate strength in this type of case is evaluated by:

• how specific the asserted claims are to a biosimilar’s critical quality attributes or clinical protocols
• whether the prior art record is strong enough for an obviousness combination
• how consistently the court handles claim construction that narrows contested terms

Amgen’s strategic posture

Amgen’s litigation posture generally reflects:

• a high willingness to contest validity with robust expert records
• parallel non-infringement arguments rooted in product-specific comparability

---

Which other cases or settlements does 1:18-cv-00924 resemble in industry practice?

Pattern matching for business impact

Many Genentech v. Amgen matters in the biotech space follow:

• early claim construction focus
• heavy expert discovery around product comparability and labeled practice
• settlement once a claim construction or summary judgment motion reduces the probability of a lasting injunction

This case’s commercial effect is best measured by whether it results in:

• an enforceable injunction
• a design-around path for Amgen
• a license with royalty economics that can be forecast for future biosimilar launches

---

What generic entry risks exist for Amgen’s challenged product post-litigation?

Second-wave entry

If Amgen’s biosimilar path is cleared, it tends to accelerate:

• additional biosimilar applicants with similar molecules or indications
• competitive pricing pressure
• payer and provider switching for high-volume oncology and supportive-care settings

If Genentech prevails, it can:

• chill additional filings
• delay entry by years depending on whether the decision covers core method claims and composition claims

---

What is the likely business outcome and commercial impact of the case?

If Genentech wins

Typical result patterns include:

• injunctions barring commercial launch or expansion
• settlement royalties that reflect the risk-adjusted probability of injunction
• licensing structures that buy peace while preserving the patentee’s core exclusivity

If Amgen wins

Typical commercial consequences include:

• launch or expansion with fewer constraints
• reduced settlement leverage for future challengers
• a more predictable market share ramp for Amgen and competitors

---

Key Takeaways

• Genentech v. Amgen Inc., No. 1:18-cv-00924, is a patent enforcement dispute in the biotech/biosimilar arena where claim construction and validity outcomes determine whether Amgen faces launch/injunction constraints.
• The practical decision points are (1) what patents were asserted, (2) how claim terms were construed, and (3) whether infringement and validity theories survived dispositive motion practice.
• Business impact depends less on docket volume and more on whether the court narrowed claims in ways that enable a product design-around or clears Amgen’s launch timeline.

---

FAQs

1. What happens to a biosimilar launch if the court narrows the asserted claims in a Genentech v. Amgen case?
   If narrowed claim scope excludes required product or method elements, non-infringement becomes more likely and commercial launch risk declines.

2. How do claim construction rulings change settlement leverage in biosimilar patent litigation?
   Construction that limits key terms tends to reduce damages/injunction probability and drives faster settlement or stipulations.

3. Do method-of-use claims depend on FDA labeling or real-world prescribing?
   Many disputes hinge on the interaction between the asserted claim elements and what is practiced in approved labeling and typical clinical use.

4. What invalidity theories are most common in these Genentech patent disputes?
   Obviousness using combinations of prior art and written description/enablement challenges to the asserted claim scope are frequent.

5. How does a court decision in one biosimilar patent case influence related litigation by other entrants?
   It can shift expectations on validity and claim scope, affecting settlement posture and the willingness to invest in launch timing.

---

References

1. United States District Court for the District of Delaware. Genentech, Inc. v. Amgen Inc., No. 1:18-cv-00924 (docket and filings).